ch.oddb.org
 
Apotheken | Hôpital | Interactions | LiMA | Médecin | Médicaments | Services | T. de l'Autorisation
Information professionnelle sur Vantas®:Orion Pharma AG
Information professionnelle complèteDDDimprimé 
Composit.Forme gal.Indic./emploiPosolog./mode d'empl.Contre-Ind.PrécautionsInteract.Grossesse
Apt.conduiteEffets indésir.SurdosagePropriétésPharm.cinét.Donn.précl.RemarquesNum. Swissmedic
TitulaireMise à jour 
H01CA03 - HistrelinATC-DDD Version 2016. Source: WHO
H - Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins

This group comprises all hormonal preparations for systemic use, except:
- Insulins, see A10.
- Anabolic steroids, see A14.
- Catecholamines, see C01C and R03C.
- Sex hormones, see G03.
- Sex hormones used in treatment of neoplastic diseases, see L02.
- Metreleptin used for treatment of complications of leptin deficiency in patients with generalised lipodystrophy is classified in A16AA.

The DDDs are generally based on the treatment or diagnosis of endocrine disorders.

H01 - Pituitary and Hypothalamic Hormones and Analogues
 
H01C - Hypothalamic Hormones

This group comprises hypothalamic hormones; extracts, purified natural hormones and synthetic analogues.
Hypothalamic hormones used as diagnostic agents for pituitary function are classified in V04CD.

H01CA - Gonadotropin-Releasing Hormones

Buserelin, goserelin, histrelin, leuprorelin, and triptorelin are classified in L02AE Gonadotropin releasing hormone analogues.
Gonadorelin used as diagnostic agent is classified in V04CM.

The DDD of nafarelin is based on the treatment of endometriosis. No other DDDs have been assigned, due to the highly variable dosages used.

H01CA03 - Histrelin
2024 ©ywesee GmbH
Einstellungen | Aide | FAQ | Identification | Contact | Home